AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis

 
• By Sue Sutter
  
Drug Review Profile: Fotivda
AVEO's Fotivda made it to the US market only after the FDA resolved lingering concerns about the drug's impact on overall survival.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews